Concepedia

Author

Sanela Tarabar

Pfizer (United States)ORCID

Also Known As

S. Tarabar, Sanela G. Tarabar, Sanela Tarabar

18

Publications

807

Citations

13

H-Index

20

Concepts

All Affiliations

Pfizer (United States)Yale UniversitySkin Cancer FoundationPfizer (United Kingdom)University of Louisville
ST

About

Sanela Tarabar is an author at Pfizer (United States) specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

146

2

Immunology

2

2

117

3

Pharmacology

2

2

46

4

Endocrinology

1

1

29

5

Obstetrics

1

1

29

Sanela Tarabar

×

14

Publications

798

Citations

13

H-Index

YearCitations

Pharmacological reversal of a pain phenotype in iPSC-derived sensory neurons and patients with inherited erythromelalgia

Lishuang Cao, Aoibhinn McDonnell, Anja Nitzsche,

Science Translational Medicine

2016

195

Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults

Allison Thompson, Erik Lamberth, Joseph M. Severs,

Vaccine

2019

100

Inherited erythromelalgia due to mutations in<i>SCN9A:</i>natural history, clinical phenotype and somatosensory profile

Aoibhinn McDonnell, Betsy R. Schulman, Zahid Ali,

Brain

2016

93

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Liver‐Targeting Acetyl‐CoA Carboxylase Inhibitor (PF‐05221304): A Three‐Part Randomized Phase 1 Study

Arthur Bergman, Santos Carvajal‐Gonzalez, Sanela Tarabar,

Clinical Pharmacology in Drug Development

2020

66

Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study

Megan N. Landis, Mark Arya, Stacy Smith,

British Journal of Dermatology

2022

60

Hearing Loss in Migrant Agricultural Workers

Peter Rabinowitz, Kanta Sircar, Sanela Tarabar,

Journal of Agromedicine

2005

57

Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study

Christopher Tehlirian, Ravi Shankar Prasad Singh, Vivek Pradhan,

Journal of the American Academy of Dermatology

2022

51

Evaluation of a Janus kinase 1 inhibitor, PF‐04965842, in healthy subjects: A phase 1, randomized, placebo‐controlled, dose‐escalation study

Elena Peeva, Martin R. Hodge, Elizabeth Kieras,

British Journal of Clinical Pharmacology

2018

45

First-in-Human Assessment of the Novel PDE2A PET Radiotracer <sup>18</sup>F-PF-05270430

Mika Naganawa, Rikki N. Waterhouse, Nabeel Nabulsi,

Journal of Nuclear Medicine

2016

30

Safety, Pharmacokinetic, and Pharmacodynamic Evaluation After Single and Multiple Ascending Doses of a Novel Selective Androgen Receptor Modulator in Healthy Subjects

Indranil Bhattacharya, Sanela Tarabar, Yali Liang,

Clinical Therapeutics

2016

29

Page 1